Azyter: first macrolide preparation for ocular use

Azyter eye drops are preservative-free.
Azyter eye drops are preservative-free.

Azithromycin is now available as eye drops for the treatment of purulent bacterial or trachomatous conjunctivitis. Azyter (azithromycin) is presented in single-dose units containing 15mg/g of the active ingredient. Administered twice daily for 3 days, it has a shorter dose regimen than many other ophthalmic anti-infectives. As a macrolide, azithromycin has a broad spectrum of activity. It is effective against the majority of bacteria responsible for common eye infections, including Gram-positive cocci (eg, Staphylococcus aureus), Gram-negative species (eg, Haemophilus influenzae) and intracellular pathogens (eg, Chlamydia trachomatis).

In a randomised, double-blind study in 670 children aged 1–10 years with conjunctivitis caused by Chlamydia trachomatis, the 60-day clinical cure rate achieved with azithromycin eye drops was non-inferior to that achieved with an oral azithromycin dose (96.3% vs 96.6%).

Azithromycin eye drops were also evaluated in a randomised, investigator-blinded study in adults and children with purulent bacterial conjunctivitis. Participants received azithromycin drops twice daily for 3 days or tobramycin 0.3% drops every 2 hours for 2 days then 4 times daily for 5 days. The clinical cure rate for azithromycin at day 9 in the per-protocol analysis (n=471) was non-inferior to that of tobramycin (87.8% vs 89.4%), with a similar microbiological resolution rate.

View Azyter drug record

Further Information: Spectrum Thea Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...